Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326172 | 1.00 | LMNA (0.55) | LMNAHTTKMT2AHRH3NPSR1 | |
| SCHEMBL3326452 | 0.97 | LMNA (0.52) | LMNAHTTKMT2AHRH3NPSR1 | |
| SCHEMBL3325775 | 0.97 | LMNA (0.52) | LMNAHTTKMT2AHRH3NPSR1 | |
| SCHEMBL3325780 | 0.97 | LMNA (0.52) | LMNAHTTKMT2AHRH3NPSR1 | |
| SCHEMBL3327455 | 0.88 | HRH3 (0.53) | HRH3POLB | |
| SCHEMBL3330189 | 0.86 | HRH3 (0.52) | HTTKMT2AHRH3MEN1 | |
| SCHEMBL3324027 | 0.86 | HRH3 (0.52) | HTTKMT2AHRH3MEN1 | |
| SCHEMBL3324024 | 0.86 | HRH3 (0.52) | HTTKMT2AHRH3MEN1 | |
| SCHEMBL3330185 | 0.86 | HRH3 (0.52) | HTTKMT2AHRH3MEN1 | |
| SCHEMBL3330494 | 0.86 | ALDH1A1 (0.53) | LMNAKMT2AHRH3NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | LMNA 1114/4885HTT 1420/4885KMT2A 291/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | LMNA 1114/4885HTT 1420/4885KMT2A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.